The month ahead: December’s upcoming events
Party season approaches; but first, conferences.
Regeneron keeps up its co-stimulatory crusade
The company’s CD38 x CD28 MAb is among recent clinical trial entrants.
AstraZeneca shores up its Tagrisso defences
The Hutchmed-originated savolitinib moves towards its first US approval.
AbbVie has Met phase 3, again
The next-generation telisotuzumab adizutecan joins teliso-V in late-stage development.
ESMO 2024 – J&J eyes Rybrevant colorectal expansion
Early data on Rybrevant plus chemo have spurred a quick leap into pivotal trials.
The month ahead: August’s remaining events
Following its odronextamab knockback, Regeneron now faces a delay to linvoseltamab.
Apollomics shifts to a smaller niche
The group abandons plans in lung cancer with Met exon 14 skipping, to focus on Met amplifications.
ASCO 2024 – J&J flies towards a more convenient Rybrevant
Paloma-3 data suggest subcutaneous Rybrevant might have an edge over the intravenous formulation.
